Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 19:11:1243-1252.
doi: 10.2147/PPA.S137052. eCollection 2017.

Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products

Carlos M González  1 , Loreto Carmona  2 , Javier de Toro  3 , Enrique Batlle-Gualda  4 , Antonio I Torralba  5 , María J Arteaga  6 , Luis Cea-Calvo  6
Affiliations

Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products

Carlos M González et al. Patient Prefer Adherence. .

Erratum in

Abstract

Objective: The aim of this study was to explore perceptions of patients with rheumatic diseases treated with subcutaneous (SC) biological drugs on the impact on daily life and satisfaction with current therapy, including preferred attributes.

Methods: A survey was developed ad hoc by four rheumatologists and three patients, including Likert questions on the impact of disease and treatment on daily life and preferred attributes of treatment. Rheumatologists from 50 participating centers were instructed to handout the survey to 20 consecutive patients with rheumatoid arthritis (RA), axial spondyloarthritis (ax-SpA), or psoriatic arthritis (PsA) receiving SC biological drugs. Patients responded to the survey at home and sent it to a central facility by prepaid mail.

Results: A total of 592 patients returned the survey (response rate: 59.2%), 51.4% of whom had RA, 23.8% had ax-SpA, and 19.6% had PsA. Patients reported moderate-to-severe impact of their disease on their quality of life (QoL) (51.9%), work/daily activities (49.2%), emotional well-being (41.0%), personal relationships (26.0%), and close relatives' life (32.3%); 30%-50% patients reported seldom/never being inquired about these aspects by their rheumatologists. Treatment attributes ranked as most important were the normalization of QoL (43.6%) and the relief from symptoms (35.2%). The satisfaction with their current antirheumatic therapy was high (>80% were "satisfied" or "very satisfied"), despite moderate/severe impact of disease.

Conclusion: Patients with rheumatic diseases on SC biological therapy perceive a high disease impact on different aspects of daily life, despite being highly satisfied with their treatment; the perception is that physicians do not frequently address personal problems. Normalization of QoL is the most important attribute of therapies to patients.

Keywords: biological drugs; emotional well-being; patient’s satisfaction; quality of life; rheumatic diseases.

PubMed Disclaimer

Conflict of interest statement

Disclosure MJA and LC-C are full employees at Merck Sharp & Dohme (MSD) of Spain. The rest of the authors received honoraria from MSD, Spain, as advisors for the design, implementation, and data interpretation of the survey. CMG has received honoraria for lectures for MSD, Spain. EB-G has served as a consultant for BMS, Roche, and MSD, Spain, and has received honoraria for lectures or educational presentations for Abbvie, UCB, Roche, Pfizer, and BMS. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Perceived impact of rheumatic disease, by gender (A), disease duration (B), and source of care (C). Note: Bottom numbers in bars represent the percentage of patients reporting that their rheumatic disease has a moderate-to-severe impact on different aspects of daily life.
Figure 1
Figure 1
Perceived impact of rheumatic disease, by gender (A), disease duration (B), and source of care (C). Note: Bottom numbers in bars represent the percentage of patients reporting that their rheumatic disease has a moderate-to-severe impact on different aspects of daily life.
Figure 2
Figure 2
Patients’ attribution of importance to each treatment feature. Note: Results are expressed in percentage of respondents. Abbreviation: QoL, quality of life.
Figure 3
Figure 3
Patients’ satisfaction with current antirheumatic therapy. Notes: Bars represent the percentage of patients into each category for the different features. Note that, for space reasons, the categories “unsatisfied” and “very unsatisfied” have been combined in the figure. Abbreviation: QoL, quality of life.
Figure 4
Figure 4
Patients’ satisfaction with current antirheumatic therapy, by the perception on impact on quality of life (moderate/severe versus none/mild). Note: Bottom numbers in bars represent the percentage of patients reporting being satisfied or very satisfied with each treatment aspect. Abbreviation: QoL, quality of life.
See this image and copyright information in PMC

References

    1. Badley EM, Rasooly I, Webster GK. Relative importance of musculoskeletal disorders as a cause of chronic health problems, disability, and health care utilization: findings from the 1990 Ontario Health Survey. J Rheumatol. 1994;21(3):505–514. - PubMed
    1. Yelin E, Callahan LF. The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups. Arthritis Rheum. 1995;38(10):1351–1362. - PubMed
    1. Alonso J, Ferrer M, Gandek B, et al. IQOLA Project Group Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project. Qual Life Res. 2004;13(2):283–298. - PubMed
    1. Sprangers MA, de Regt EB, Andries F, et al. Which chronic conditions are associated with better or poorer quality of life? J Clin Epidemiol. 2000;53(9):895–907. - PubMed
    1. Kvien TK, Uhlig T. Quality of life in rheumatoid arthritis. Scand J Rheumatol. 2005;34(5):333–341. - PubMed